References
- O'Dell JR, Nepom BS, Haire C, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998; 57(4): 209–13
- Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002, 61 (4): 290–7
- Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997: 350(9074): 309–18
- O'Dell JR. Combination DMARD therapy with hydroxy chloroquine, sulfasalazine, and methotrexate. Clin Exp Rheumatol 1999; 17(6 Supp1 18): S53–8
- Ruddy S, Harris ED Jr, Sledge CB, et al, eds. Kelley's textbook of rheumatology. 6th ed. Philadelphia: WB Saunders, 2001
- Callen JP. Neutrophilic dermatoses. Dermatol Clin 2002; 20(3): 409–19
- Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998; 19(4): 667–85, viii
- Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 2002; 31 (5): 251–9
- Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis 1987; 46(9): 658–63
- Casey AT, Crockard HA, Pringle J, et al. Rheumatoid arthritis of the cervical spine: current techniques for management. Orthop Clin North Am 2002; 33(2): 291–309
- Saag KG. Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 2002; 4(3): 218–25
- O'Dell JR, Blakeiy KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxy chloroquine. Arthritis Rheum 2001; 44(10): 2235–41
- O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997; 40(5): 842–8
- Keystone EC. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27(2): 427–43
- Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor, receptor (p75)-Fc fusion protein. N Engl J Med 1997: 337(3): 141–7
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti- tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase 111 trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932–9
- Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1): 35–45 [Erratum, Arthritis Rheum 2003; 48(3): 855]
- Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44(9): 1977–83
- Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002: 46(3): 614–24
- Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000: 43(1): 155–63